Comparison of periodontal wound healing/regeneration by recombinant human fibroblast growth factor‐2 combined with β‐tricalcium phosphate, carbonate apatite, or deproteinized bovine bone mineral in a canine one‐wall intra‐bony defect model
Yoshinori Shirakata, Fumiaki Setoguchi, Kotaro Sena, Toshiaki Nakamura, Takatomo Imafuji, Yukiya Shinohara, Masayuki Iwata, Kazuyuki Noguchi
Abstract
Abstract Aim To evaluate periodontal wound healing/regeneration of one‐wall intra‐bony defects treated with recombinant human fibroblast growth factor‐2 (rhFGF‐2) and beta‐tricalcium phosphate (β‐TCP), carbonate apatite (CO 3 Ap), or deproteinized bovine bone mineral (DBBM) in dogs. Materials and Methods The stability of rhFGF‐2 adsorbed onto the bone substitutes was evaluated by Enzyme‐Linked Immunosorbent Assay (ELISA). One‐wall intra‐bony defects (5 × 5 × 5 mm) created in five adult male beagle dogs were treated with rhFGF‐2 alone (rhFGF‐2), rhFGF‐2 with β‐TCP (rhFGF‐2/β‐TCP), rhFGF‐2 with CO 3 Ap (rhFGF‐2/CO 3 Ap), or rhFGF‐2 with DBBM (rhFGF‐2/DBBM). Histological outcomes (e.g., linear length of new cementum adjacent to the newly formed bone with inserting collagen fibres [NA] as the primary outcome) were evaluated at 10 weeks post surgery. Results Significantly higher amount of rhFGF‐2 was adsorbed onto CO 3 Ap compared with β‐TCP. Among the treatment groups, the rhFGF‐2/DBBM group showed the highest amount of periodontal tissue regeneration. The rhFGF‐2/DBBM group showed significantly greater formation of NA (3.22 ± 0.40 mm) compared with rhFGF‐2 (1.17 ± 1.00 mm, p < .01) group. Additionally, new bone area in the rhFGF‐2/DBBM group (9.78 ± 2.30 mm 2 ) was significantly higher than that in the rhFGF‐2 (5.08 ± 1.26 mm 2 , p < .01), rhFGF‐2/β‐TCP (5.91 ± 1.27 mm 2 , p < .05), and rhFGF‐2/CO 3 Ap (6.51 ± 1.49 mm 2 , p < .05) groups. Slight ankylosis was found in the rhFGF‐2/β‐TCP (1/9 sites), rhFGF‐2/CO 3 Ap (3/10 sites), and rhFGF‐2/DBBM (1/9 sites) groups. Conclusions Within their limitations, the present data indicate that DBBM seems to be a suitable carrier for rhFGF‐2 and that rhFGF‐2/DBBM treatment promotes favourable periodontal regeneration compared with rhFGF‐2, rhFGF‐2/β‐TCP, and rhFGF‐2/CO 3 Ap treatments in one‐wall intra‐bony defects.